Analysts from financial services firm Taylor Collison recently released a report that reiterated their buy rating on Mach7 Technologies Ltd (ASX: M7T). Here’s why analysts think this ASX tech stock is poised to rocket in 2020 and beyond.
What does Mach7 do?
Mach7 provides digital data management solutions for hospitals that allow a clear and complete view of patient records. The company’s flagship Management Studio platform aims to improve diagnosis delivery, reduce care delivery delays and costs, and improve patient outcomes.
Mach7’s Vendor Neutral Archive is essential to the company’s core enterprise imaging solutions for physicians and radiologists. The company also sells picture archive and communications systems and has 2 revenue models in software as a service and upfront licensing.
Mach7 currently employs more than 40 staff in the US and Asia-Pacific region and the company estimates that it has a global addressable market worth in excess of $US3 billion. According to Mach7, the advantages of its technologies include customers controlling their own data, ease of installation, low hardware requirements, and an attractive price point.
How has Mach7 performed?
Recently, Mach7 provided the market with its second-quarter report for FY20. The company saw its second consecutive quarter of positive cash flow with $0.5 million reported for the second quarter of FY20.
Other highlights of the Mach7 quarterly report included $3.6 million in cash receipts and a successful capital raise of $20 million. The company also managed to extend contracts with 7 existing customers and signed 2 new clients in the second quarter.
Analysts from Taylor Collison reiterated their buy rating on Mach7 with a high level of conviction on the company’s outlook. With Mach7’s upgrade on expected cash flow for FY20, analysts lifted their price target for the company to $1.17.
Analyst forecasts included additional contract wins with large institutions over the next 12 months and cited Mach7’s strong pipeline of opportunities. Quarterly cash receipts are expected to remain volatile, however, free cash flow is expected to be sustainable over the medium to long term.
Using 3-year consensus forecasts, analysts also think that Mach7 remains significantly undervalued in comparison to the likes of Pro Medicus Limited (ASX: PME) and Volpara Health Technologies Ltd (ASX: VHT).
Should you buy?
The Mach7 share price has surged more than 30% since the start of 2020 and is well-poised for further upside as it trades near 52-week-highs. In my opinion, companies offering auxiliary services to the health sector have tremendous opportunities with lucrative addressable markets.
Although the research from Taylor Collison is highly regarded, I think it would be risky for investors to jump the gun and buy shares in Mach7. Instead, I think a prudent strategy would be to keep Mach7 on your ASX watchlist and do your due diligence before making an investment decision.
The post Here’s why analysts are bullish on this ASX tech stock appeared first on Motley Fool Australia.
Here are 5 other stocks you should keep on your watchlist.
Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.7% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares to buy now
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2020
- 5 Stocks for Potentially Building Wealth After 50
Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of MACH7 FPO. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. and VOLPARA FPO NZ. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2020